The escalating cost of pharmaceuticals in Pakistan has placed essential medications out of reach for many, particularly the economically vulnerable. Factors such as high inflation, low-income levels, and insufficient health insurance exacerbate this crisis. Patients frequently struggle to afford life-saving drugs, impacting their health and quality of life. To address these challenges, the government must take decisive action by implementing price caps, promoting generic drugs, offering subsidies, and supporting local pharmaceutical manufacturing. Effective public sector procurement and quality control are essential to ensure affordability and accessibility. Strengthening the Drug Regulatory Authority of Pakistan (DRAP) is critical to enhancing transparency, preventing price gouging, and ensuring an adequate supply of essential medicines through regulatory reforms. Public awareness campaigns can play a vital role in educating communities about the benefits of generic drugs and cost-effective alternatives, empowering patients to make informed decisions and reduce unnecessary expenses. Incentivizing domestic production of pharmaceuticals will reduce reliance on imports, stabilize prices, and foster innovation in the local industry. Collaborations between the public and private sectors can further improve drug distribution, efficiency, and affordability. By adopting these measures, Pakistan can alleviate the financial burden on patients, ensure equitable access to medications, and promote better public health outcomes.